Ultimovacs ASA

Ultimovacs is a biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the nearly universal cancer antigen telomerase, investigated in five randomized Phase 2 trials. UV1 is being developed as a therapeutic cancer vaccine for use in combination with other immuno-oncology drugs, which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 670 patients at 100 clinics in 15 countries in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is publicly listed at Euronext Oslo ...